Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi Pharmaceutical Co. Ltd.

www.daiichipharm.co.jp

Latest From Daiichi Pharmaceutical Co. Ltd.

Deal Watch: AbbVie Offloads Three Cystic Fibrosis Candidates To Sionna

Plus deals involving Abeona/Beacon, TuHura/Kintara, Crosswalk/Codexis, Lantheus/Life Molecular Imaging as well as tech transfer agreements and small deals involving Pfizer, Sanofi and Ipsen.

Deal Watch Business Strategies

From Whiskey To Cancer Drugs: George Nakayama’s Unusual Journey

From extricating Daiichi Sankyo from the Ranbaxy acquisition to enabling the rapid development of blockbuster Enhertu, George Nakayama has had a winding career path through multiple key strategic positions and decisions. He shares his experience and insights, and a good dose of humor, in this exclusive interview.

Leadership Strategy

BioNTech Eyes First Oncology Approvals By 2026

The biotech's CEO told the J.P. Morgan Healthcare Conference that the company aims to have multiple oncology products on the market by 2029, but it plans to retain a large presence in vaccines as well.

Business Strategies ImmunoOncology

Five Key Takeaways From Merck’s Q2 Earnings Release

Keytruda and Gardasil lead Merck’s growth story, although Lagevrio’s ongoing decline placed a drag on quarterly performance. Lung cancer is driving Keytruda’s momentum outside the US.

Sales & Earnings Pricing Debate
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register